The Comprehensive Care for Alzheimer’s Act


In the 117th Congress, AIM worked closely with bipartisan congressional champions to develop and introduce the Comprehensive Care for Alzheimer’s Act, critical legislation to streamline the complicated health care maze for people living with dementia and their caregivers. Thanks to AIM advocates, there was tremendous bipartisan support for the bill (134 House cosponsors, 39 Senate cosponsors) in the 117th Congress and again when it was reintroduced in the 118th Congress.


Recognizing the broad bipartisan congressional support for the bill and the dementia care planning model, on July 31, 2023 the Centers for Medicare & Medicaid Services (CMS) announced an initiative to improve the way dementia care is delivered for people living with Alzheimer’s disease and other dementia. This test initiative, the Guiding an Improved Dementia Experience (GUIDE) Model, will be run through the Center for Medicare & Medicaid Innovation (CMMI). 

This CMS initiative is consistent with the bipartisan Comprehensive Care for Alzheimer’s Act, which aims to provide access to dementia care management. Dementia care management is an important tool to improve the quality of care, ease the challenges of Alzheimer’s caregiving and reduce costs. 

While we have more to accomplish, we can join with our hardworking advocates to celebrate the step forward toward providing high-quality dementia care for all those impacted by Alzheimer’s and other dementia.

Two Advocates Outside

Be a Champion in the Fight to End Alzheimer’s

Our voices are stronger together. Help AIM advance legislation to improve the lives of people impacted by Alzheimer’s and all other dementia.

  • Share your story with elected officials
  • Engage on social media
  • Write a letter to the editor

Federal Priorities

Access to Treatment

A restrictive Centers for Medicare & Medicaid Services (CMS) policy that only applies to those living with Alzheimer’s disease is blocking access to FDA-approved treatments. CMS must reverse its unprecedented decision that denies Medicare coverage of current and future treatments for Alzheimer’s.

A National Response to Alzheimer’s and Other Dementia

The bipartisan NAPA Reauthorization Act and the Alzheimer’s Accountability and Investment Act would build on the progress made over the last decade by continuing to promote rapid research and improve the delivery of clinical care and services for people living with Alzheimer’s.